ClinicalTrials.gg
RecruitingNCT06929923Updated Aug 12, 2026

Pro-2-Cool Pivotal Trial II

An interventional study of Pro2Cool Device and Sham Cooling Garment Device in Concussion, Mild, sponsored by TecTraum Inc.. Recruiting at 3 sites in United States. Open to participants aged 13 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by TecTraum Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
13 Years to 21 Years
Sex
All
01

Study summary

This study is being conducted to determine the clinical safety and efficacy of Pro-2-Cool mediated head and neck cooling when applied after concussion and improved symptomatology among adolescent athletes as quantified by post-concussion symptom severity (PCSS) score.

Read the detailed description

This is a multi-center, prospective, randomized, double-blinded, dual-arm comparative study enrolling up to a total of 66 patients (approximately 33 patients in the treatment arm and 33 patients in the control arm) following sports-related, concussion.

02

Conditions studied

  • Concussion, Mild

Browse trials for

Keywords

  • Non-invasive hypothermic therapy
  • Sports-related concussion
03

In context

Brain Concussion

637 studies on the registry are indexed under Brain Concussion; 163 are open to participants now.

This study's planned enrollment of 66 is close to the median of 63 across 446 interventional studies indexed under Brain Concussion.

Browse Brain Concussion studies →

Lead sponsor

TecTraum Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, 13-21 years of age
  2. Confirmed concussion diagnosis consistent with American Congress Rehabilitation Medicine guidelines 21, without any of the following:

    • Glasgow Coma Scale (GCS) score of less than 13 at 30 minutes post-injury
    • Loss of consciousness greater than 30 minutes
    • Post-traumatic amnesia lasting over 24 hours
  3. Glasgow Coma Scale (GCS) ≥ 13 at the time of initial injury for study enrollment.
  4. Post-Concussion Symptom Scale Score minimum of 15
  5. Initial provider visit is within 7 days of injury
  6. In generally good health as confirmed by medical history and determined by site investigator or designated trained healthcare professional under the supervision of the principal investigator.
  7. Has obtained per protocol and as required per Institutional Review Board

Exclusion criteria

Exclusion Criteria:

  1. Age \< 13 years or > 21 years
  2. Inability to understand the study requirements or provide
  3. Cleared to return to play during initial visit
  4. Prior participation in a Pro2Cool Clinical Study
  5. Serious traumatic brain injury as evidenced by worsening symptoms:

    • Vomiting > 2 episodes following injury
    • Seizure
    • Hospitalization
    • Radiology scan indicating brain bleed
    • Slurred speech which has not resolved within 72 hours of concussive injury
  6. Physical (e.g., head or neck injury that requires medical treatment) or mental disability hindering adequate response to assessment of symptoms
  7. Hemodynamic instability/medical condition requiring further acute life-saving medical intervention
  8. History of psychiatric disorder that includes suicide attempts within the last 6 months, unmanaged depression or anxiety, hospitalization for psychiatric treatment within the last 6 months
  9. Known brain mass, intracranial hemorrhage, skull fracture
  10. Scalp abnormalities including laceration or bleeding
  11. Presence of ventriculoperitoneal (VP) shunt
  12. Known hematological , including, but not limited to: multiple myeloma, leukemia, and lymphoma
  13. Known history of Reynaud's Disease compromised liver function, cold agglutination, cold sensitivity, cryoglobulinemia, cryofibrinogenemia, and/or a history of severe migraines
  14. Known or disclosed pregnancy or breast-feeding
  15. Sustains another head or neck injury at the time of concussive injury which requires medical treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Pro2Cool intervention with standard of care

    The treatment arm will receive standard of care for concussion along with 30 minutes of headneck cooling in the clinic while being monitored for side effects. The Pro2Cool® will be used to provide head and neck cooling.

    Device: Pro2Cool Device

  • Sham comparator
    Sham Pro2Cool with standard of care

    The control arm will receive standard of care like the treatment group, along with 30 minutes of sham Pro2Cool® placement in the clinic while being monitored for side effects. The Pro2Cool® device will not be used to provide neck cooling; a sham cooling garment device will be placed with impaired cooling function (only to the head), with sham treatment temperature being set to 19°C (instead of the therapeutic 6°C specification).

    Device: Sham Cooling Garment Device

Interventions

  • DevicePro2Cool Device

    The Pro2Cool Device is a non-invasive hypothermic therapy ("cold therapy") device that provides localized cooling of the head and neck. Water and isopropyl alcohol cooled to 6°C by the chiller assembly circulate through the cooling garment to create conductive heat transfer from the scalp and carotid arteries, thus achieving cooling of the brain.

  • DeviceSham Cooling Garment Device

    The sham cooling garment device will be placed with impaired cooling function (only to the head), with sham treatment temperature being set to 19°C (instead of the therapeutic 6°C specification). There will be no thermal nylon barrier that will be used and flow to the neck bladder will be closed.

06

What researchers measure

Primary outcomes

  1. Change quantified by post-concussion symptom severity (PCSS) assessment score

    Time frame: Post-injury to 72-hour follow-up

Secondary outcomes

  1. Number of adverse events associated with the head-and-neck cooling treatment

    Time frame: Treatment to 72-hour follow-up

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.

Of 264 interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 16, 2025
StartActual
Feb 20, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06929923
Lead sponsor
TecTraum Inc.
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
Feb 20, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

John Zak, MD, MBA
Contact
jzak@tectraum.com
216-789-7676
Brian Reilly, MD
principal investigator · Children's Hospital Medical Center of Akron

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion